VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update
VolitionRx reported Q3 2026 revenue of approximately $1.6 million, up 157% year-over-year from $0.6 million, driven by increased recognition of deferred revenue. Losses narrowed materially: operating loss fell 35% to $3.3 million and net loss to $3.8 million, aided by 14% lower operating expenses and a 28% headcount reduction. The company also prepaid its $7.5 million convertible note in cash. Cash stands at only $2.4 million despite $5.2 million of ATM proceeds in the quarter, and the CEO took a further salary cut to 50% of original level while the board cut cash fees at least 50%, underlining funding pressure pending a substantial licensing deal.
Key figures
- Revenue
- $1.6 million
- Revenue Yoy
- 157%
- Cash
- $2.4 million
- Net loss
- $3.8 million
- Operating loss
- $3.3 million
- Opex change yoy
- -14%
- Atm net proceeds
- $5.2 million
- Cash prior year end
- $1.1 million
- Ceo base salary cut
- 50%
- Headcount reduction
- 28%
- Net loss prior year
- $5.4 million
- Detecseps program value
- €6.3 million
- Convertible note prepaid
- $7.5 million
- Feline assay sensitivity
- 86%
- Feline assay specificity
- 97%
- Operating loss prior year
- $5.1 million
- Mced mrd addressable market
- $36 billion
- Feline lymphoma milestone payment
- $5 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.